Lv1
20 积分 2024-07-10 加入
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
7个月前
已完结
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
7个月前
已完结
The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045
8个月前
已完结
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
9个月前
已完结
Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
9个月前
已完结
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention
10个月前
已完结
皖公网安备34019202002308
